semaglutide 50 mg oral taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial FDA approves Novo Nordisk's oral

Identifying and Preparing Your Injection Sites for Semaglutide Common subcutaneous injection sites for semaglutide include the abdomen, thighs, and back of the upper arms

Whats involved in that process

doi:10.1056/NEJMoa2307563 11 Kosiborod MN et al.: Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

If the Phase 3 trials (TRIUMPH series) read out as expected, MHRA approval is plausible in late 2026 or 2027

They are breaking out and shaking up the entire healthcare scene

The convergence of antioxidant, vascular, metabolic, and performance benefits supports considering watermelon as a functional food with therapeutic promise for cardiometabolic health